CAMBRIDGE, Mass. – BioScale Inc., an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles (AMMP™) assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.

The data presented in the article show clearly that the BioScale platform offers a robust and rapid method for measuring recombinant standards or endogenously derived proteins from both tissue culture and mouse xenograft tumor lysates.

“We have hit another milestone for BioScale with publication of the Millennium pharmacodynamic biomarker results in Analytical Biochemistry”

.Dr. Zhong-Hua Yan, Senior Scientist at Millennium Pharmaceuticals: The Takeda Oncology Company, was the lead author of the article. Dr. Michael Bembenek, Associate Director, Lead Discovery, oversaw the comparative analyses that were performed in the study. For this research, pharmacodynamic biomarkers for both proteasome and phosphoinositol 3-kinase inhibition were used. The two pathway biomarkers were compared with either AlphaScreen or LI-COR Western blot assays. In addition to being a robust and rapid method for measuring recombinant standards or endogenously derived proteins from both tissue culture and mouse xenograft tumor lysates, BioScale’s ViBE Protein Analysis Workstation showed that the sensitivity obtained with the BioScale platform compares favorably with LI-COR Western blot and AlphaScreen technologies. Furthermore, the use of the ViBE eliminated the labor-intensive effort of Western blot analysis and is devoid of the optical and other endogenous interfering substances derived from lysates of xenograft tumors typically observed with AlphaScreen.

“We have hit another milestone for BioScale with publication of the Millennium pharmacodynamic biomarker results in Analytical Biochemistry,” said Brett Masters, BioScale’s Chief Technology Officer. “We look forward to continued execution of our commercialization plans for the ViBE and believe the simplicity and flexibility of the platform will provide scientists the ability to perform a wide range of protein analysis, not only with more sensitive, reproducible data, but with the power to work in complex samples more efficiently than ever before.”

The complete article can be located on the Analytical Biochemistry website.

About ViBE Platform

Powered by AMMP Technology, the ViBE platform enables advancements in protein research. AMMP (Acoustic Membrane MicroParticle) technology is a unique mechanical integration of magnetic microparticles, a universal sensor and acoustic science delivering a proprietary, non-optical protein detection and quantitation technique that is highly robust and versatile, with ease of methods transfer from traditional assay formats. The ViBE Workstation is the ideal tool for reliable, unattended sample analysis including reagent additions, incubation and real-time results with walkaway operation and is well suited for a variety of applications including biomarker discovery and development, bioprocess engineering and manufacturing.

ViBE Protein Analysis Workstations are currently being used by major pharmaceutical and biotech companies and in world-renowned research institutes to perform a wide range of protein analysis applications not only with more sensitive, reproducible data, but with the power to work in complex samples more quickly and efficiently than ever before. For more information or to get a copy of the poster presentation contact info@bioscale.com, call 877-539-VIBE (8423), or visit the company’s website at www.bioscale.com.

About BioScale

BioScale is a life science company that develops, manufactures and promotes a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE platform enables highly-sensitive detection and quantitation of proteins in complex samples used in pre- clinical and clinical research, bioprocess, patient point-of-care and personalized medicine applications. Founded in 2002, the Company is headquartered in Cambridge, MA. For more information, visit www.bioscale.com.

Forward Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding BioScale’s future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company’s ability to obtain financing, the development and commercialization of ViBE systems, the prospects of the Company’s protein analytics platform, the Company’s strategies to develop and commercialize protein analytics systems and the breadth of the Company’s technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. BioScale is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

BioScale logo, AMMP and ViBE are trademarks of BioScale, Inc